DSM-Firmenich
Netherlands · CH1216478797 · reports in EUR · Europe
The answers
From the annual report for the year to Dec 31, 2024. Each line says what it is based on.
- Is it growing?Good
- Revenue +20% in the year to Dec 31, 2024, on the year before.
- Is it a good business?To watch
- It earned 1.2% on its shareholders' equity in the year to Dec 31, 2024.
- Is it safe?Good
- Equity is 67% of its assets, and operations brought in cash in the year.
- Is the price fair?n/a
- Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.
The year
Year to Dec 31, 2024, consolidated, in EUR.
revenue
operating margin
net profit
Year by year
As filed; an earlier year can differ from its own report when the company restated it.
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Revenue | €10.6B | €12.8B |
| Operating profit | −€497M | €561M |
| Earnings per share | €9.14 | €0.94 |
| Cash from operations | €1.3B | €1.8B |
| Capital spending | €555M | €645M |
| Cash | €2.5B | €2.7B |
| Total assets | €34.3B | €33.7B |
| Equity | €23.1B | €22.7B |
What they do
In the company's own words, from the annual report.
The Group’s operating businesses are organized into four Business Units: Perfumery & Beauty; Taste, Texture & Health; Health, Nutrition & Care; and Animal Nutrition & Health.
Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.